AU697612B2 - Post exposure prevention of HIV - Google Patents

Post exposure prevention of HIV Download PDF

Info

Publication number
AU697612B2
AU697612B2 AU26331/95A AU2633195A AU697612B2 AU 697612 B2 AU697612 B2 AU 697612B2 AU 26331/95 A AU26331/95 A AU 26331/95A AU 2633195 A AU2633195 A AU 2633195A AU 697612 B2 AU697612 B2 AU 697612B2
Authority
AU
Australia
Prior art keywords
international
administration
document
day
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26331/95A
Other languages
English (en)
Other versions
AU2633195A (en
Inventor
Bo Oberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/251,316 external-priority patent/US5612319A/en
Priority claimed from SE9500348A external-priority patent/SE9500348D0/xx
Application filed by Medivir AB filed Critical Medivir AB
Publication of AU2633195A publication Critical patent/AU2633195A/en
Application granted granted Critical
Publication of AU697612B2 publication Critical patent/AU697612B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU26331/95A 1994-05-31 1995-05-11 Post exposure prevention of HIV Ceased AU697612B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/251316 1994-05-31
US08/251,316 US5612319A (en) 1994-05-31 1994-05-31 Postexposure prevention of HIV infection or seroconversion
SE9500348 1995-02-01
SE9500348A SE9500348D0 (sv) 1995-02-01 1995-02-01 Post exposure prevention of HIV
PCT/SE1995/000524 WO1995032983A1 (fr) 1994-05-31 1995-05-11 Prevention de l'infection a vih chez des patients ayant ete exposes a ce virus

Publications (2)

Publication Number Publication Date
AU2633195A AU2633195A (en) 1995-12-21
AU697612B2 true AU697612B2 (en) 1998-10-15

Family

ID=26662215

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26331/95A Ceased AU697612B2 (en) 1994-05-31 1995-05-11 Post exposure prevention of HIV

Country Status (6)

Country Link
EP (1) EP0763048A1 (fr)
JP (1) JPH10501217A (fr)
AU (1) AU697612B2 (fr)
CA (1) CA2190862A1 (fr)
IL (1) IL113846A (fr)
WO (1) WO1995032983A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
EA011039B1 (ru) 2004-12-30 2008-12-30 Медивир Аб Приемлемые для лечения вич соединения
EP1679076A1 (fr) * 2005-01-06 2006-07-12 Medivir Ab Composés pour le traitement de HIV
GB0513835D0 (en) * 2005-07-07 2005-08-10 Medivir Ab HIV inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008001A1 (fr) * 1987-04-16 1988-10-20 Aktiebolaget Astra Nucleosides et analogues de nucleosides, compositions et procedes pharmaceutiques permettant la preparation des composes
EP0391411A2 (fr) * 1989-04-06 1990-10-10 Bristol-Myers Squibb Company 3-Méthyl nucléosides substitués comme agents antiviraux en position 3'
WO1992006102A1 (fr) * 1990-10-02 1992-04-16 Medivir Ab Derives de nucleoside

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008001A1 (fr) * 1987-04-16 1988-10-20 Aktiebolaget Astra Nucleosides et analogues de nucleosides, compositions et procedes pharmaceutiques permettant la preparation des composes
EP0391411A2 (fr) * 1989-04-06 1990-10-10 Bristol-Myers Squibb Company 3-Méthyl nucléosides substitués comme agents antiviraux en position 3'
WO1992006102A1 (fr) * 1990-10-02 1992-04-16 Medivir Ab Derives de nucleoside

Also Published As

Publication number Publication date
CA2190862A1 (fr) 1995-12-07
IL113846A (en) 1999-07-14
AU2633195A (en) 1995-12-21
IL113846A0 (en) 1995-08-31
JPH10501217A (ja) 1998-02-03
EP0763048A1 (fr) 1997-03-19
WO1995032983A1 (fr) 1995-12-07

Similar Documents

Publication Publication Date Title
US4861759A (en) Antiviral compositions and methods
AU608824B2 (en) Agent for the prophylaxis and therapy of retroviral infections
EP0437554B1 (fr) Composition pharmaceutique et methode d'inhibition de virus
HUT67031A (en) Process for production of preparations for treatment of hiv infection
SE450251B (sv) Xantatforeningar for terapeutisk anvendning, nya xantatforeningar samt terapeutiska kompositioner innehallande dessa foreningar
HU201672B (en) Process for producing pharmaceutical compositions comprising podophyllotoxin
AU640511B2 (en) Hexa-n-(o-hydroxybenzyl) neomycin b for inhibiting human retroviruses and for the treatment of aids
EP0355825A2 (fr) Système du traitement viral
AU697612B2 (en) Post exposure prevention of HIV
JPH02204414A (ja) ２′，３′―ジデオキシプリンヌクレオシド／プリンヌクレオシドホスホリラーゼ阻害剤の組合せ療法および組成物
CA1318850C (fr) Produits pharmaceutiques
US3624215A (en) 8-substituted theophyllines as anti-anxiety agents
DE3873232T2 (de) Ein dideoxynukleosid enthaltendes arzneimittel.
KR970705563A (ko) 항바이러스제로서의 4-(2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일)-2-시클로펜텐-1-메탄올 숙시네이트(4-(2-Amino-6-(Cyclopropylamino)-9H-Purin-9-yl)-2-Cyclopentene-1-Methanol Succinate as Antiviral Agent)
DE3881864T2 (de) Antivirale zusammensetzungen mit aromatischen polycyclischen dionen sowie methode zur behandlung retroviraler infektionen.
US5434142A (en) Method of treatment for muscular dystrophy
US5612319A (en) Postexposure prevention of HIV infection or seroconversion
JPH01132526A (ja) 薬剤組成物
JPH08503938A (ja) 原虫性感染症治療用のアトバクオンとプログアニルとのコンビネーション
Spence et al. St. Louis encephalitis in southern Ontario: laboratory studies for arboviruses.
Rim et al. Anthelmintic effect of oxantel pamoate and pyrantel pamoate
DE4320597A1 (de) Verwendung von Polyphosphaten zur antiviralen Therapie und als Immunmodulatoren
DE3141970A1 (de) Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen
EP0555302A1 (fr) Procede de traitement des maladies demyelinisantes
US4174407A (en) Antiviral agent

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired